Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$87.29 USD
-0.38 (-0.43%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $87.32 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.29 USD
-0.38 (-0.43%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $87.32 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance
by Zacks Equity Research
Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.
Here's Why Investors Should Buy Edwards Lifesciences Now
by Zacks Equity Research
Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Is Edwards Lifesciences Corporation (EW) a Great Growth Stock?
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) is a company that might be well-positioned for future earnings growth.
Here's Why Investors Should Buy Align Technology (ALGN) Now
by Zacks Equity Research
Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
by Zacks Equity Research
Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Varian (VAR) Rides on Oncology and Proton Therapy Businesses
by Zacks Equity Research
Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.
Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
STERIS (STE) Banks on Organic Growth, Competition Intense
by Zacks Equity Research
STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2
by Zacks Equity Research
OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
CVS Health Grows on Specialty Pharmacy amid Retail Woes
by Zacks Equity Research
CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.
Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down
by Zacks Equity Research
Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.
Haemonetics Banks on Solid Plasma & Haemonetics Management
by Zacks Equity Research
Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.
Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.
STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up
by Zacks Equity Research
STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.
BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates
by Zacks Equity Research
BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.
Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.